Solid Lipid Nanoparticles and Nanostructured Lipid Carriers of Loratadine for Topical Application: Physicochemical Stability and Drug Penetration through Rat Skin

Melike Üner1*, Ecem Fatma Karaman1 and Zeynep Aydoğanuş2

Istanbul University, Faculty of Pharmacy, 1Department of Pharmaceutical Technology, 2Department of Analytical Chemistry, 34116 Beyazıt, Istanbul, Turkey

*For correspondence: Email: melikeuner@yahoo.com; Tel: +90 212 4400000; Fax: +90 212 4400252

Received: 13 June 2013 Revised accepted: 15 March 2014

Abstract

Purpose: To prepare solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) of loratadine (LRT) for the treatment of allergic skin reactions.

Methods: SLN and NLC were prepared by high pressure homogenization method. Their entrapment efficiency (EE) and loading capacity (LC) were determined. The physical stability of nanoparticles was investigated during 6 months of storage at room temperature (RT), 4 and 40 °C. Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC) and laser diffraction (LD) were used for the investigation of drug:excipient compatibility, thermal behaviour and particle size of the nanoparticles. In vitro release and ex vivo skin penetration of LRT were studied. Nanoemulsions (NE) were also prepared and characterized for comparison.

Results: Nanoparticles sizes ranged from 0.222 ± 0.011 μm to 0.252 ± 0.014 μm (D50 as a value based on the volume distribution, the maximum particle diameter below which 50 % of the sample volume exists) They were obtained with high drug payloads (> 90.67 %). LRT was compatible with the other excipients after 6 months. Particle size did not significantly alter particularly at RT. The highest release rate was obtained with NE (1.339 ± 0.026 mcg/ml/h) followed by NLC (1.007 ± 0.011 mcg/ml/h) and SLN (0.821 ± 0.012 mcg/ml/h), indicating anomalous transport (p < 0.05). Penetration profiles of LRT through skin were statistically similar for SLN and NLC (p > 0.05). NE showed the highest penetration rate (0.829 ± 0.06 mcg/cm²/h) (p < 0.05).

Conclusion: SLN and NLC of LRT are alternative formulations for immediate treatment of allergic skin reactions with prolonged drug delivery via reservoir action.

Keywords: Loratadine, Transdermal delivery, Controlled drug delivery, Solid Lipid nanoparticles, Nanostructured lipid carriers, Allergy

INTRODUCTION

Histamine which is present as a tissue hormone, especially in the skin and lungs in human, is also found in the bee poison and the salivary secretion of biting insects [1,2]. When allergic skin reactions occur or immediately after being bitten by an insect, excess histamine is released causing itching and formation of skin weals and flares. Even though histamine is rapidly metabolised in the body, the effects caused by the subsequent release may last for a considerable period of time which severely affects the well-being of the person concerned.
The second generation of H1 receptor blocking agents including loratadine (LRT), can be used for inhibiting histamine release from the basophilic granulocytes and the mastocytes where histamine is stored in tissues [3]. LRT displays various side effects including several allergic reactions including rash, hives, itching, difficulty in breathing, tightness in the chest, swelling of the mouth or face and dizziness during systemic administration by oral route. Thus, topical preparations of LRT for skin application would be advantageous for the management of skin reactions. However, LRT has a poor penetration through the skin. This limitation may be overcome by incorporation of LRT into colloidal drug carrier systems like solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) [4,5].

SLN and NLC are advantageous colloidal drug carrier systems over their colloidal counterparts such as polymeric nanoparticles, liposomes and microemulsions [4]. SLN are produced using solid lipids including high-melting point glycerides or waxes, replacing liquid lipid used in emulsions. Thus, SLN introduce prolonged delivery of actives by reservoir action. However, SLN may have some limitations in drug loading capacity depending on the solubility of the drug in the solid lipid and/or drug loss during storage due to lipid crystallization to the stable β-modification and relatively high water content. NLC, the second generation of SLN are produced by using spatially incompatible lipids together. Incorporation of liquid lipid into the solid structure ensures to overcome possible limitations related to SLN. SLN and NLC are sophisticated colloidal drug carrier systems suitable for skin applications due to their various desirable effects on skin. Occlusive properties of SLN and NLC on skin provide increase in drug penetration particularly via skin moisturization. They can transfer drugs into deeper layers of the skin, provide reservoir action and sustained drug delivery. They are also well suited for use on damaged or inflamed skin since they are based on non-irritant and non-toxic lipids. Thus, topical preparations of SLN and NLC have been increasingly attracted by industry for years and they are introduced to the market of European Community. In the meantime, high pressure homogenization which can be employed avoiding use of organic solvents has an excellent reproducibility in the large scale production for SLN and NLC as a cost-effective technique.

The objective of this study was to incorporate LRT into SLN and NLC with the aim to achieve skin penetration of LRT and to provide reservoir action for the treatment of disorders or diseases of the skin caused by excessive histamine release.

**EXPERIMENTAL**

**Materials**

Loratadine (LRT), Miglyol® 812s (Sasol Germany GmbH, Germany) and TegoCare® 450 (Evonik Goldschmidt GmbH, Germany) were thankfully provided by TEVA Pharmaceutical Works Private Ltd. (Hungary), Kale Kimya (Kocaeli, Turkey) and Elkasan Kimyevi Maddeler Pazarlama A.Ş. (Istanbul, Turkey), respectively. 1-hexadecanol was purchased from Fluka. All the other chemicals used were of analytical grade.

**Preparation of SLN and NLC**

High pressure homogenization method was employed for production of nanoparticles [4,5]. TegoCare® 450 (2 %w/w) and 1-hexadecanol (15 % w/w) were used as surfactant and solid lipid for production of placebo SLN (PSLN), respectively. Solid lipid was melted at 75 °C. Aqueous surfactant solution at the same temperature was added to the melted lipid using an Ultra-Turrax T25 homogenizer (Jahnke und Kunkel GmbH, Germany) at 20,000 rpm for 1 min. The coarse emulsion was passed through an APV-Lab 2000 high pressure homogenizer (Poland) with two steps (50 bar and 1500 bar, respectively) for three cycles. In the case of placebo NLC (PNLC), Miglyol® 812s as liquid lipid was added to the solid lipid to reduce the fraction of 1-hexadecanol (1:2 w/w, respectively), i.e. the total lipid content stayed unchanged. PNLC was produced in exactly the same manner under the same conditions. Preparations were poured into transparent silanized vials and capped tightly. Vials were stored at RT, 4 and 40 °C in the dark. In the case of drug loaded nanoparticles (SLN and NLC), 1 % LRT (w/w) of the total formulation was added to the lipophilic phase to reduce its fraction.

Only liquid lipid (Miglyol® 812s) was used instead of solid lipid in PNE and NE produced by using the same technique and conditions for comparison.

**Entrapment efficiency and loading capacity of SLN and NLC**

EE (%) and LC (%) of nanoparticles were determined by analysing the concentration of free LRT in the dispersion medium [6,7]. Nanoparticle dispersion was diluted with water at a certain rate. It was centrifuged at 13 000 rpm (Heraeus Biofuge Primo R Centrifuge, Thermo 13(5): 654
Fisher Scientific, Germany) for 40 min. Proper amount of supernatant was taken and diluted to 10 ml with a mixture of phosphate buffer (PBS, pH 7.4) and propylene glycol mixture (60:40). The solution was analysed by HPLC. EE and LC were calculated using Eqs 1 and 2,

\[
EE = \frac{(W_i - W_f)W_i}{W_i} \times 100 \quad \text{(1)}
\]

\[
LC = \frac{((W_i - W_f)W_p)}{W_p} \times 100 \quad \text{(2)}
\]

where \(W_i\) and \(W_p\) are the amounts of initial drug and lipid used for the production of the nanoparticles, respectively, while \(W_f\) is the amount of free drug detected in the aqueous supernatant.

**FTIR analysis**

Determination of interaction between LRT and the other ingredients of SLN and NLC was investigated by FTIR after 6 months [8]. Nanoparticle dispersion was diluted with water and centrifuged at 13 000 rpm for 40 min. The residue was transferred into glass plates and was kept at 4 °C over night for elimination of aqueous phase of dispersions. The sample was used for FTIR analysis. Residues obtained from SLN and NLC, and pure LRT were separately scanned over a wave number range of 4000 to 650 cm\(^{-1}\) at a resolution of 4 cm\(^{-1}\) in the transmission mode in a Perkin Elmer 100 FTIR instrument (UK) equipped with Perkin Elmer Spectrum Version 6.0.2 Software.

**DSC analysis**

DSC analysis was employed on pure lipid, placebo and drug loaded nanoparticles in order to investigate crystallization behaviour of lipid and drug-lipid interaction. 25 µl samples equal to 3-4 mg solid content were weighed into standard sealed aluminium pans of the apparatus (DSC 204 F1 Phoenix\(^{®}\), Netzsch, Germany) and heated from 20 °C to 80 °C with a heating rate of 10 K/min under a nitrogen flow rate of 20 ml/min. Melting peaks and enthalpies were calculated using the DSC 204 F1 software. Crystalline state determination of interaction between LRT and the other ingredients of SLN and NLC was investigated by FTIR after 6 months [8]. Nanoparticle dispersion was diluted with water and centrifuged at 13 000 rpm for 40 min. The residue was transferred into glass plates and was kept at 4 °C over night for elimination of aqueous phase of dispersions. The sample was used for FTIR analysis. Residues obtained from SLN and NLC, and pure LRT were separately scanned over a wave number range of 4000 to 650 cm\(^{-1}\) at a resolution of 4 cm\(^{-1}\) in the transmission mode in a Perkin Elmer 100 FTIR instrument (UK) equipped with Perkin Elmer Spectrum Version 6.0.2 Software.

**Particle size measurement**

Particle size distribution of placebo and drug loaded formulations were determined in water by using a laser diffractometer equipped with Hydro 2000MU wet sample dispersion unit (Malvern Mastersizer Instrument, UK). Samples were diluted before the measurements (n = 3). Measurement medium was water with a refractive index of 1.33. Particle size of formulations were analysed as volumetric distribution (D10, D50 and D90).

**In vitro drug release**

Dialysis bag diffusion technique was used for determination of In vitro LRT release from SLN, NLC and NE under sink condition [7]. A sample (1 g) was placed in the regenerated cellulose dialysis bag (Mw cut-off at 3.500 Da, Spectra/Por\(^{®}\) dialysis membrane, U.S.A) and both ends of the bag were tightly closed. The bag was immersed into a flask containing 200 ml dissolution medium (PBS/propylene glycol, 60:40) that was placed in an agitating water bath. We used 40 % propylene glycol in the receptor phase since previous studies used receptor phases containing up to 50 % propylene glycol for in vitro release and ex vivo penetration experiments (10-12). The system was maintained at 37 ± 0.5 °C and agitated at 60 rpm. Samples (1 ml each) were collected at predetermined time intervals for 48 h. Cumulative amounts of drug in the sample were detected by HPLC after proper dilution. This study was replicated 6 times for each formulations. The mean cumulative amount of LRT in dissolution medium was plotted as a function of time.

Release profiles were evaluated using different models in order to determine one that best describes release mechanism of drug: zero order, which describes the release rate independent of drug concentration; first order, which describes the release rate dependent of concentration gradient; Higuchi, which is based on the Fick’s law of diffusion; Korsmeyer–Peppas which indicates the Fickian diffusion and non-Fickian diffusion, where \(n\) is the release exponent, indicative of mechanism of drug release (Eqs 4 - 7) [8].

**Zero order:**

\[
Q_t = Q_0 + k_{0t} \quad \text{.............. (4)}
\]

**First order:**

\[
Q_t = Q_\infty (1 - e^{-k_{1t}}) \quad \text{.............. (5)}
\]

**Higuchi square-root:**

\[
Q_t = Q_0 + k_{ht}t^{1/2} \quad \text{.............. (6)}
\]

**Korsmeyer-Peppas:**

\[
\log[Q_t/Q_\infty] = \log k + n\log t \quad \text{.............. (7)}
\]

where \(Q_t\) and \(Q_\infty\) are amounts of drug released at time, \(t\), and in the release medium at \(t = 0\), respectively, \(k_0\), \(k_1\) and \(k_{ht}\) are release constants of the zero order, the first order and Higuchi.
square-root models, respectively, \( Q/Q\infty = \frac{k}{n} \) fractional release of drug, \( k \) and \( n \) = kinetic constant and diffusional release exponent indicative of the release mechanism.

**Penetration through excised rat skin**

Full thickness abdominal skins of Wistar albino rats (150 - 200 g) were obtained after rats were sacrificed [13]. Skins were depilated and dermal surfaces were carefully cleaned to remove subcutaneous tissues without damaging the epidermal surface. Underlying fatty tissue was removed by blunt dissection. The experimental protocol was approved by the Local Ethical Committee of Animal Experiments in Experimental Medical Research Institute of Istanbul University (2011/157) following the Council of Europe [14].

The formulation (1 g) was applied to the donor compartment on the surface of rat skins between two halves of Franz-type diffusion cell. Receptor phase was 33.2 ml PBS/proplylene glycol (60:40) at 37 ± 1°C [11,12]. Amount of LRT penetrated through skin was determined from the samples collected at predetermined time intervals for 48 h by HPLC (\( n = 3 \)). The steady state flux of LRT (\( \mu g/cm^2/h \)) was calculated from the slope of the linear portion of the plot of the cumulative amount permeated versus time.

**Analytical quantification of LRT by HPLC**

Quantification of LRT was made using a Shimadzu LC-2010HT HPLC apparatus (Japan) at RT. Data acquisition was performed with the software of Shimadzu LC-2010HT. Separations were provided by using a Phenomenex C18 column (250 mm × 4.6 mm i.d., 5 μm particle size). A mobile phase consisting of acetonitrile and water (80:20) was used at a flow rate of 0.8 ml/min. Injection volume was 20 μL. Calibration curve was gained from 6 solutions of LRT in PBS/proplylene glycol (60:40) at 0.1-1.0 μg/ml concentration range by detection at 200 nm. The retention time of LRT was ~2 min.

**Statistical analysis**

Data obtained from studies on in vitro drug release and drug penetration through excised rat skin were evaluated using GraphPad Prism software and one-way ANOVA to determine differences between profiles. \( P < 0.05 \) was set as the level of significance.

---

**RESULTS**

**LRT calibration**

The calibration curve was linear over the concentration range of 0.5 – 8.0 μg/ml (\( y = 4.602 \) e-06x + 62.378 \( r^2 = 0.9989 \)) by HPLC. The concentration of LRT in each samples were calculated from the corresponding regression equations.

**EE and LC of SLN and NLC**

EE of SLN and NLC was found as 90.67 ± 0.48 and 93.27 ± 0.44 % when LC values were obtained as 6.06 ± 0.03 and 6.22 ± 0.03 %, respectively.

**FTIR spectra**

Pure LRT spectra showed very intense several characteristic IR absorption bands [8]. Their assignments of LRT were as follows: 1700.93 cm\(^{-1}\) (C=O stretching band), 1643.37 cm\(^{-1}\) (C=N stretching band), 1560.15 cm\(^{-1}\) - 1434.13 cm\(^{-1}\) (C=C stretching vibrations of benzene ring), 1385.05 cm\(^{-1}\) (N=C stretching band), 1222.30 cm\(^{-1}\) and 996.60 cm\(^{-1}\) (C=O stretching bands), 862.83 cm\(^{-1}\) (=C–H stretching band), 762.87 cm\(^{-1}\) (C–Cl stretching band). These findings have also been reported in various studies by different research groups [15,16].

It was observed that C=O stretching bands caused by aliphatic ester structure of triglycerides displayed sharp peaks at 1768.71 and 1722.16 cm\(^{-1}\) for SLN and NLC, respectively. C-H and O-H stretching bands of triglycerides were detected at 3295.28 cm\(^{-1}\) - 2835.43 cm\(^{-1}\). The same peaks were detected at the same wave number range after 6 months of storage of SLN and NLC at RT, 4 and 40°C.

**DSC thermograms**

Heating of the bulk lipid caused thermal transitions. DSC thermogram of 1-hexadecanol showed sharp endothermic peak at 55.57 ºC corresponding to the melting of β polymorphic forms of the crystal lipid (Table 1). The onset value and the theoretical melting enthalpy of the solid lipid was determined as 49.47 ºC and 235.76 J/g. According to data obtained from DSC experiments on formulations after their preparation, melting points of nanoparticles were detected to decrease to lower temperatures with broader peaks compared to bulk lipid by giving variable enthalpy values indicating several thermal transitions as well. Decrease in melting points of PSLN and SLN formulations was...
Table 1: DSC parameters of bulk lipid, placebo and drug loaded nanoparticles after 6 months of storage at room temperature (RT), 4 and 40 °C

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Storage temp (°C)</th>
<th>Enthalpy ΔH (J/g)</th>
<th>Melting point (°C)</th>
<th>CI (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bulk 1-hexadecanol</td>
<td>RT</td>
<td>235.76</td>
<td>55.57</td>
<td>100</td>
</tr>
<tr>
<td>PSLN</td>
<td>RT</td>
<td>19.96</td>
<td>51.78</td>
<td>56.44</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>20.67</td>
<td>51.83</td>
<td>58.45</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>17.51</td>
<td>50.65</td>
<td>49.51</td>
</tr>
<tr>
<td>SLN</td>
<td>RT</td>
<td>22.79</td>
<td>50.47</td>
<td>64.44</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>23.42</td>
<td>50.22</td>
<td>66.23</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>19.96</td>
<td>50.51</td>
<td>56.44</td>
</tr>
<tr>
<td>PNLC</td>
<td>RT</td>
<td>14.39</td>
<td>48.24</td>
<td>40.69</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>14.82</td>
<td>47.93</td>
<td>41.91</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>13.08</td>
<td>47.86</td>
<td>36.99</td>
</tr>
<tr>
<td>NLC</td>
<td>RT</td>
<td>15.71</td>
<td>46.79</td>
<td>44.42</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>15.91</td>
<td>47.53</td>
<td>44.99</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>12.43</td>
<td>46.16</td>
<td>35.15</td>
</tr>
</tbody>
</table>

RT = room temperature, CI = crystallinity indice

Figure 1: D10 (□), D50 (■) and D90 (▲) values of placebo and drug loaded nanoparticles and NEs after 6 months of storage. Note: Laser diffraction (LD) data = volume distribution

Table 2: Determination coefficients for drug release from SLN, NLC and NE with diffusion exponents of release profiles for Korsmeyer Peppas model

<table>
<thead>
<tr>
<th>Formulations</th>
<th>Zero order</th>
<th>First order</th>
<th>Higuchi</th>
<th>Korsmeyer-Peppas (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLN</td>
<td>0.9044</td>
<td>0.6977</td>
<td>0.9773</td>
<td>0.9848 (0.5281)</td>
</tr>
<tr>
<td>NLC</td>
<td>0.9345</td>
<td>0.7742</td>
<td>0.9904</td>
<td>0.9932 (0.4824)</td>
</tr>
<tr>
<td>NE</td>
<td>0.8828</td>
<td>0.7225</td>
<td>0.9850</td>
<td>0.9912 (0.4604)</td>
</tr>
</tbody>
</table>

R² = correlation coefficient; n = diffusion exponent of release profile (slope). Best fits were bolded.

detected as 5 °C when incorporation of liquid lipid causes more decrease in case of PNLC and NLC. Table 1 lists various parameters obtained from samples after 6 months of storage at RT, 4 and 40 °C.

Particle size

D50 values of placebo formulations (PSLN, PNLC and PNE) obtained from LD were in 0.229 - 0.258 µm size range in their production week. LRT incorporation into formulations did not significantly alter their particle size. SLN displayed the highest D50 value (0.252 ± 0.008 µm) followed by NLC (0.248 ± 0.010 µm) and NE (0.222 ± 0.002 µm). Figure 1 presents data obtained from placebo and drug loaded nanoparticles and NE formulation after 6 months of storage at different temperatures.

In vitro drug release

LRT release was the lowest with SLN followed by NLC and NE, respectively as can be seen in
Release rate of LRT from the different formulations were 0.821 ± 0.018, 1.007 ± 0.011 and 1.339 ± 0.012 mcg/ml/h.

Korsmeyer-Peppas was shown to be the best fitting model for all formulations (Table 2). A combined pattern of diffusion and erosion release mechanism (anomalous non-Fickian transport, 0.45 ≤ n < 0.89) was found for SLN and NLC which shows the ability of the system for controlled drug release. NE was also displayed the same release mechanism closer to 0.45 n value, which indicates predominantly diffusional drug release.

Penetration through excised rat skin

The highest penetration for LRT through skin occurred with NE followed by NLC and SLN (p < 0.05) (Figure 3). However, insignificant difference was obtained between LRT penetration profiles of SLN and NLC. Drug penetration reached to a steady state flux between 8th and 24th hours. In this period, penetration rates were found as 0.707 ± 0.008, 0.725 ± 0.010 and 1.123 ± 0.014 mcg/cm²/h for SLN, NLC and NE, respectively.

DISCUSSION

Drug payload of SLN and NLC was high as it was desired for a colloidal drug carrier system. Addition of liquid lipid to the lipophilic phase resulted in a slight increase in drug payload as reported earlier [7,8]. This was attributed to the higher solubility of LRT in liquid lipid compared to the solid lipid. Interaction between LRT and excipients were physical. FTIR spectra of samples exhibited peaks of LRT and triglycerides in the finger print area indicating chemical compatibility during 6 months of storage at RT, 4 and 40 °C.

Oil content in NLC caused enhancement of drug release rate from nanoparticles. Existence of liquid lipid in NLC spoiled formation of crystal structure in the matrix and makes drug liberation to a medium where the drug is readily soluble. In the case of NE, drug release was faster since its lipophilic phase was composed of liquid lipid. Release of LRT from SLN and NLC continued at the same rate up to the end of the 8th hour which was the last sampling time of the first day of the study. Difference and decrease in release rate were detected from the 8th hour. Biphasic pattern of release profiles can be explained by non-Fickian diffusion (anomalous transport) described by Korsmeyer-Peppas model. When nanoparticles were exposed to the release
medium, drug close to the surface of nanoparticles was released by diffusion - within the first 4 h and erosion of nanoparticles appeared gradually. Subsequent release from the 8th hour continued in a linear manner (r = 0.9867 and r = 0.9892 for SLN and NLC, respectively).

Lipophilic phase composed of oil in NE led faster drug penetration rate through skin since it provided drug release convenient after close contact with Stratum corneum. Liberation of LRT from droplets of NE was occurred more easily compared to the matrix structure of SLN and NLC as could be expected.

In a recent study, SLN and NLC were reported to exhibit a high adhesion to the stratum corneum enhancing the amount of drug which penetrated into the viable skin [19]. Lipid nanoparticles formulated in this study are expected to display an occlusive effect and reduce the trans-epidermal water loss. This will result in an enhancement in amount of drug penetrated into the skin layers.

CONCLUSION

SLN and NLC of LRT were prepared with good steric stabilization, high drug payload and crystal properties leading drug accommodation in nanoparticles during storage. SLN and NLC introduced colloidal carrier systems with desirable controlled release characteristics for LRT. It can be concluded that SLN and NLC can be used for immediate treatment of allergic skin reactions and then prolonged drug delivery via reservoir action in order to prevent excess histamin release. NE of LRT, which was produced for comparison in order to characterize SLN and NLC was also found a physically stable formulation at different storage temperatures after 6 months. It displayed the highest penetration rate through skin. Thus, it was found to have a high potential for the treatment of allergic skin reactions.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest to disclose.

ACKNOWLEDGEMENT

The authors would like to thank Biofarma Pharmaceutical Industry Co Inc, Istanbul and Argis Pharmaceutical Research and Development, Ankara for their contribution.

REFERENCES

4. Üner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie 2006; 61(5): 375-386.
17. How CW, Abdullah R, Abbasalipourkarib R. Physicochemical properties of nanostructured lipid carriers as colloidal carrier system stabilized with
polysorbate 20 and polysorbate 80. African J
